Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Stock Up More Than 9 Percent Since CFO Announced Resignation Yesterday

NEW YORK, Dec. 9 (GenomeWeb News) - Shares in Orchid Biosciences were up 6.13 percent at $11.94 in mid-afternoon trading one day after the company announced that CFO Mike Spicer has resigned.

 

In all, the shares have climbed 9.5 percent since Orchid made the announcement on Wednesday.

Orchid said Spicer, who is also senior vice president of finance at the firm, said he plans to join a publicly traded biopharmaceutical company. The company has promoted Joseph Warusz to vice president of financial planning and analysis, and has given him "additional financial oversight" until a replacement for Spicer has been found.

 

In the same statement, Orchid reiterated its revenue expectation of about $60 million for the fourth quarter.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.